Cardiovascular scientific production in Spain and in the European and global context (2003-2007).

Introduction And Objectives: The publication of research articles has increased considerably in recent years in all biomedical fields. The present study examines the position of Spanish quality research in cardiology in the European and world context, and its evolution during the 5-year period 2003-2007.

Methods: Using the Science Citation Index Expanded of Thomson Reuters as data source, we compared Spanish cardiovascular scientific production with that of the rest of countries in the European Union and of the most important countries worldwide, along with relative productivity as per number of inhabitants and Gross Domestic Product, and the number of citations in the journals of the <> area of the Journal Citation Reports (CCS-JCR).

[Role of bosentan in patients with chronic venous thromboembolic pulmonary hypertension].

Background And Objective: Chronic thromboembolic pulmonary hypertension (CTEPH) has a dismal prognosis when there are no central pulmonary thrombi amenable to surgical thromboendarterectomy. Pulmonary vasodilators could be useful in this setting. Initial experience with bosentan in a small group of patients with CTEPH has shown favourable results on the short term (3 to 6 months), but long-term effects remain unknown.

[Mechanical cardiac assist devices and heart transplantation. Treatment indications and the current situation in Spain].

Despite advances in all areas of cardiology, the incidence of heart failure increases each year. Pharmacologic treatment, cardiac resynchronization therapy, and heart failure surgery have resulted in prolonged survival in these patients and in symptomatic improvement. However, in more advanced phases of the disease, these therapeutic options become less effective.

[Heart failure: etiology and approach to diagnosis].

In spite of its high prevalence and the huge burden it imposes on health care systems, heart failure is a clinical syndrome that has not yet been defined satisfactorily. In actual practice, diagnosis requires the presence of typical signs and symptoms along with data from complementary tests that indicate definite cardiac dysfunction. In this article we review current concepts of the disease, stages of development, common underlying causes, and the value of different diagnostic tests.

[Is heart transplantation for primary cardiac sarcoma a useful therapeutic option?].

Primary cardiac sarcomas are rapidly progressive malignant tumors. No good therapeutic option is known. In recent years, heart transplantation has sometimes been performed in selected patients with cardiac sarcoma.